

# MDR Conformity Assessment Routes

**Notified Body Assessments** 

### Contents


Class Is/Im/Ir devices	2	
Class IIa devices	4	
Class IIb Annex VIII rule 12 devices	8	
<ul> <li>Class IIb implantable – Well-Established Technologies (WET)</li> </ul>	10	
<ul> <li>Class IIb non-implantable non rule 12 devices (non WET)</li> </ul>	10	
<ul> <li>Class IIb implantable devices (excluding WET)</li> </ul>	14	
Class III non-implantable devices	16	
Class III implantable devices	18	
Custom-made Class III implantable devices	20	
Custom-made devices (excluding custom-made Class III implantable devices)	22	
<ul> <li>Class I devices (excluding Class Is/Im/Ir devices)</li> </ul>	23	

#### DISCLAIMERS:

Information presented in the conformity assessment flow charts and tables below is based on our current understanding of the MDR requirements at the time of publishing this document; subject to change. The tables do not cover assessments under the conformity routes Annex X (Type Examination) and Annex XI Part B (Product Verification) which may require additional tests or examinations of the devices. The tables present a generalization of the requirements based on the classification of devices and some exceptions may apply.

bsi.

# Class Is/Im/Ir devices



#### CLASS Is/Im/Ir DEVICES

Class Is/Im/Ir	Initial Conformity		รเ	JRVEILLAN	CE	
devices	Assessment	Y1	Y2	Y3	Y4	Y5
QMS Audits	Yes	Yes	Yes	Recert	Yes	Yes
Microbiology Audits	Yes*	N/A	Yes*	N/A	Yes*	N/A
Technical Documentation Assessment	N/A	N/A	N/A	N/A	N/A	N/A
Clinical Evaluation Consultation Procedure (Article 54)	N/A	N/A	N/A	N/A	N/A	N/A
Consultations (Rule 14, Rule 18, Rule 21)	N/A	N/A	N/A	N/A	N/A	N/A
Summary of Safety and Clinical Performance (Article 32)	N/A	N/A	N/A	N/A	N/A	N/A

\*if sterile or re-usable surgical instruments

Clinical Evaluation Report updates	Updated a	s per Manuf	acturer's clir	nical evaluat	ion plan
Post Market Clinical Follow-Up Update Report (Article 61)	Updated as per Manufacturer's PMS, PMCF plans; NB QMS audits to verify implementation of the plan by sampling complaints, vigilance information etc.				
Periodic Safety Update Report (Article 86)	N/A	N/A	N/A	N/A	N/A
Unannounced Audits (BSI policy as of Feb 2019)	At least once every 5 years				

### **Class IIa** devices Class IIa Annex XI – Part B Annex XI – Part A Annex IX QMS Production Quality Production Chapters I, III Assurance Verification Annex IX Chapter II Annex II and Annex III **Technical Documentation** Technical Documentation Assessed per device category Assessed per device category Declaration of conformity (Annex IV) **CE Marking** (Annex V) CE 0086 or 2797

#### CLASS IIa NON-IMPLANTABLE DEVICES

Class IIa	Initial Conformity		SL	JRVEILLAN	CE	
non-implantable devices	Assessment	Y1	Y2	Y3	Y4	Y5
QMS Audits	Yes	Yes	Yes	Recert	Yes	Yes
Microbiology Audits	Yes (if sterile)	N/A	Yes (if sterile)	N/A	Yes (if sterile)	N/A
Technical Documentation Assessment	Sample per category of devices	As per the Technical Documentation Sampling Plan				Plan
Clinical Evaluation Consultation Procedure (Article 54)	N/A	N/A	N/A	N/A	N/A	N/A
Consultations (Rule 14, Rule 18, Rule 21)	N/A	N/A	N/A	N/A	N/A	N/A
Summary of Safety and Clinical Performance (Article 32)	N/A	N/A	N/A	N/A	N/A	N/A

Clinical Evaluation Report updates	Updated as per Manufacturer's clinical evaluation plan; NB to review as per Technical Documentation Sampling Plan
Post Market Clinical Follow-Up Update Report (Article 61)	Updated as per Manufacturer's PMS, PMCF plans; NB to review as per Technical Documentation Sampling Plan
Periodic Safety Update Report (Article 86)	PSUR update required at least once every 2 years; NB to review as per Technical Documentation Sampling Plan
Unannounced Audits (BSI policy as of Feb 2019)	At least once every 5 years

Continued on page 6

### Class IIa devices continued

#### CLASS IIa IMPLANTABLE DEVICES

Class IIa	Initial Conformity		รเ	JRVEILLAN	CE	
implantable devices	Assessment	Y1	Y2	Y3	Y4	Y5
QMS Audits	Yes	Yes	Yes	Recert	Yes	Yes
Microbiology Audits	Yes (if sterile)	N/A	Yes (if sterile)	N/A	Yes (if sterile)	N/A
Technical Documentation Assessment	Sample per category of devices	As per the Technical Documentation Sampling Plan				Plan
Clinical Evaluation Consultation Procedure (Article 54)	N/A	N/A	N/A	N/A	N/A	N/A
Consultations (Rule 14, Rule 18, Rule 21)	N/A	N/A	N/A	N/A	N/A	N/A
Summary of Safety and Clinical Performance (Article 32)	Yes	Updated at least annually "if indicated"; NB to review as per Technical Documentation Sampling Plan or at the time of PSUR assessments				
Clinical Evaluation Report updates		Updated as per Manufacturer's clinical evaluation plan; NB to review updates as per Technical Documentation Sampling Plan or at the time of PSUR assessments				entation
Post Market Clinical Follow-Up Update Report (Article 61)		Updated at least annually; NB to review as per Technical Documentation Sampling Plan or at the time of PSUR assessments				the
Periodic Safety Update Report (Art	ticle 86)	Updated when necessary and at least every two years;				

 Unannounced Audits (BSI policy as of Feb 2019)
 At least once every 3 years



General Safety and Performance Requirements (Annex I) in the New Medical Device Regulation

Comparison with the Essential Requirements of the Medical Device Directive and Active Implantable Device Directive

Laurel Macomber, Senior Manager, Medical Operations Shared Services, DePuy Synthes, and Alexandra Schroeder, Product Expert, Vascular Devices Certification, BSI

Our website offers a wealth of useful resources including white papers, guidance documents and webinars.

To find out more, visit bsigroup.com/medicaldevices

BSI Transitions Medical Devices Regulation

### **BSI Transitions** al Devices Regulation × / ~ 111 😂 🤤


### MDR Documentation Submissions Best Practices Guidelines

bsi.

MI CG Devices Regulation (MDR) 1,2,3 1,21 EN 150 14971 EN 150 11607-2 EN ISO 13485 Sec. 7.5.7 EN ISO 11607-1/-2 making excellence a habit making excellence a habit.

7

## Class IIb Annex VIII Rule 12 devices




Annex VIII Rule 12 devices – All active devices intended to administer and/or remove medicinal products, body liquids or other substances to or from the body.

#### CLASS IIb ANNEX VIII RULE 12 DEVICES

Class IIb	Initial Conformity	SURVEILLANCE			CE	
Annex VIII Rule 12 devices	Assessment	Y1	Y2	Y3	Y4	Y5
QMS Audits	Yes	Yes	Yes	Recert'	Yes	Yes
Microbiology Audits	Yes (if sterile)	N/A	Yes (if sterile)	N/A	Yes (if sterile)	N/A
Technical Documentation Assessment	Sample per Generic Device Group	As per the Technical Documentation Sampling Plan				Plan
Clinical Evaluation Consultation Procedure (Article 54)	Yes, but exemptions may apply as per Article 54.2	Maybe required if any modifications to the device adversely affect the risk-benefit ratio				ice
Consultations (Rule 14, Rule 18, Rule 21)	N/A	N/A	N/A	N/A	N/A	N/A
Summary of Safety and Clinical Performance (Article 32)	N/A	N/A	N/A	N/A	N/A	N/A
Clinical Evaluation Report Updates		Updated as per Manufacturer's clinical evaluation plan; NB to review updates as per Technical Documentation Sampling Plan				1
Post Market Clinical Follow-Up Up (Article 61)	date Report	Updated as per Manufacturer's PMCF plan; NB to review updates as per Technical Documentation Sampling Plan				
Periodic Safety Update Report (Art	ticle 86)	Updated at least annually; NB to review updates as per Technical Documentation Sampling Plan				es as per

Unannounced Audits (BSI policy as of Feb 2019) At least once every 5 years

### **Class IIb implantable WET Class IIb non-implantable,** non rule 12, non WET



#### CLASS IIb IMPLANTABLE WET

Class IIb	Initial Conformity		SL	JRVEILLAN	CE	
implantable WET devices	Assessment	Y1	Y2	Y3	Y4	Y5
QMS Audits	Yes	Yes	Yes	Recert	Yes	Yes
Microbiology Audits	Yes (if sterile)	N/A	Yes (if sterile)	N/A	Yes (if sterile)	N/A
Technical Documentation Assessment	Sample per Generic Device Group	As per the Technical Documentation Sampling Plan				Plan
Clinical Evaluation Consultation Procedure (Article 54)	N/A	N/A	N/A	N/A	N/A	N/A
Consultations (Rule 14, Rule 18, Rule 21)	N/A	N/A	N/A	N/A	N/A	N/A
Summary of Safety and Clinical Performance (Article 32)	Yes	Updated at least annually "if indicated"; NB to review updates as per Technical Documentation Sampling Plan or at the time of PSUR assessments				
Clinical Evaluation Report updates		Updated as per Manufacturer's clinical evaluation plan; NB to review as per Technical Documentation Sampling Plan				
Post Market Clinical Follow-Up Update Report (Article 61)		Updated at least annually; NB to review updates as per Technical Documentation Sampling Plan or at the time of PSUR assessments				
Periodic Safety Update Report (Art	ticle 86)	Updated at least annually; submitted to NB via EUDAMED for NB review (assuming WET devices are				

 Unannounced Audits (BSI policy as of Feb 2019)
 At least once every 3 years

Continued on page 12

#### CLASS IIb NON-IMPLANTABLE, NON WET, NON RULE 12

Class IIb	Initial		รเ	JRVEILLAN	CE	
non-implantable, non-WET, non-Rule 12 devices	Conformity Assessment	Y1	Y2	Y3	Y4	Y5
QMS Audits	Yes	Yes	Yes	Recert	Yes	Yes
Microbiology Audits	Yes (if sterile)	N/A	Yes (if sterile)	N/A	Yes (if sterile)	N/A
Technical Documentation Assessment	Sample per Generic Device Group	As per the Technical Documentation Sampling Plan				ing Plan
Clinical Evaluation Consultation Procedure (Article 54)	N/A	N/A	N/A	N/A	N/A	N/A
Consultations (Rule 14, Rule 18, Rule 21)	N/A	N/A	N/A	N/A	N/A	N/A
Summary of Safety and Clinical Performance (Article 32)	N/A	N/A	N/A	N/A	N/A	N/A

Clinical Evaluation Report updates	Updated as per Manufacturer's clinical evaluation plan; NB to review updates as per Technical Documentation Sampling Plan
Post Market Clinical Follow-Up Update Report (Article 61)	Updated as per Manufacturer's PMCF plan; NB to review updates as per Technical Documentation Sampling Plan
Periodic Safety Update Report (Article 86)	Updated at least annually; NB to review updates as per Technical Documentation Sampling Plan
Unannounced Audits (BSI policy as of Feb 2019)	At least once every 5 years

bsi.

...making excellence a habit."

# Don't delay... **EXCEPTION** Standard • Dedicated

Technical Documentation Reviews for CE Marking

BSI CE-Excellence Programmes are designed for medical device manufacturers wanting to get their products to European markets efficiently and safely.



### **CE-Standard**

The CE-Standard review service allows you to work closely with your assigned BSI Product Expert on your product certification. These reviews are conducted remotely, with communication between you and your BSI Product Expert via phone and email, as required.



### **CE-Dedicated**

The CE-Dedicated review service allows you to book your technical documentation review in advance. The service is conducted remotely with your BSI Product Expert, who uses the time allocated to your company to conduct a focused review of your technical documentation. This allows you to interact with your BSI expert, providing them information during the review. The CE-Dedicated service improves the efficiency of the process, and provides predictability in your planning of the review.


Note: Our services do not guarantee a CE Marking certificate will be issued within a certain amount of working days, but are based on completing the review process with either a positive or negative recommendation. CE-Dedicated is not available for devices utilizing animal tissue, blood derivatives or medicinal substances.

For more information on our CE-Excellence services call BSI on +44 345 080 9000 or visit bsigroup.com/ce-excellence



# Class IIb implantable devices

(excluding WET)




#### CLASS IIb IMPLANTABLE NON-WET DEVICES

Class IIb	Initial Conformity		SL	JRVEILLAN	CE	
implantable non-WET devices	Assessment	Y1	Y2	Y3	Y4	Y5
QMS Audits	Yes	Yes	Yes	Recert	Yes	Yes
Microbiology Audits	Yes (if sterile)	N/A	Yes (if sterile)	N/A	Yes (if sterile)	N/A
Technical Documentation Assessment	Review for every device	N/A	N/A	N/A	N/A	N/A
Clinical Evaluation Consultation Procedure (Article 54)	N/A	N/A	N/A	N/A	N/A	N/A
Consultations (Rule 14, Rule 18, Rule 21)	N/A	N/A	N/A	N/A	N/A	N/A
Summary of Safety and Clinical Performance (Article 32)	Yes	Updated at least annually "if indicated"; NB to review at the time of PSUR reviews or substantial change reviews				

Clinical Evaluation Report updates	Updated as per Manufacturer's clinical evaluation plan; NB to review at the time of PSUR reviews or substantial change reviews
Post Market Clinical Follow-Up Update Report (Article 61)	Updated at least annually; NB to review at the time of PSUR reviews or substantial change reviews
Periodic Safety Update Report (Article 86)	Updated at least annually; submitted to NB via EUDAMED for NB review
Unannounced Audits (BSI policy as of Feb 2019)	At least once every 3 years

# Class III non-implantable devices

(including devices with medicinal substances, human tissue or animal tissue derivatives with TSE risk, Class III Rule 21 devices).




#### CLASS III NON-IMPLANTABLE DEVICES

Class III	Initial Conformity	SURVEILLANCE					
non-implantable devices	Assessment	Y1	Y2	Y3	Y4	Y5	
QMS Audits	Yes	Yes	Yes	Recert	Yes	Yes	
Microbiology Audits	Yes (if sterile)	N/A	Yes (if sterile)	N/A	Yes (if sterile)	N/A	
Technical Documentation Assessment	Review for every device	N/A	N/A	N/A	N/A	N/A	
Clinical Evaluation Consultation Procedure (Article 54)	N/A	N/A	N/A	N/A	N/A	N/A	
Consultations (Rule 14, Rule 18, Rule 21)	If applicable	Modifications to the devices may need supplementary consultations; determined on a case-by-case basis taking into account the nature of the changes proposed					
Summary of Safety and Clinical Performance (Article 32)	Yes	Updated at least annually "if indicated"; NB to review at the time of PSUR reviews or substantial change reviews					

Clinical Evaluation Report Updates	Updated as per Manufacturer's clinical evaluation plan; NB to review at the time of PSUR reviews or substantial change reviews
Post Market Clinical Follow-Up Update Report (Article 61)	Updated at least annually; NB to review at the time of PSUR reviews or substantial change reviews
Periodic Safety Update Report (Article 86)	Updated at least annually; submitted to NB via EUDAMED for NB review
Unannounced Audits (BSI policy as of Feb 2019)	At least once every 3 years

# Class III Implantable devices


(including devices with medicinal substances, human tissue or animal tissue derivatives with TSE risk, Class III Rule 21 devices).



#### CLASS III IMPLANTABLE DEVICES

Class III implantable devices	Initial Conformity Assessment	SURVEILLANCE					
		Y1	Y2	Y3	Y4	Y5	
QMS Audits	Yes	Yes	Yes	Recert	Yes	Yes	
Microbiology Audits	Yes (if sterile)	N/A	Yes (if sterile)	N/A	Yes (if sterile)	N/A	
Technical Documentation Assessment	Review for every device	N/A	N/A	N/A	N/A	N/A	
Clinical Evaluation Consultation Procedure (Article 54)	Yes, but exemptions may apply as per Article 54.2	May be required if any modifications to the device adversely affect the risk-benefit ratio					
Consultations (Rule 14, Rule 18, Rule 21)	If applicable	Modifications to the devices may need supplementary consultations; determined on a case-by-case basis taking into account the nature of the changes proposed					
Summary of Safety and Clinical Performance (Article 32)	Yes	Updated at least annually "if indicated"; NB to review at the time of PSUR assessments or substantial change reviews					
Clinical Evaluation Report Updates		Updated as per Manufacturer's clinical evaluation plan; NB to review at the time of PSUR reviews or substantial change reviews					
Post Market Clinical Follow-Up Update Report (Article 61)		Updated at least annually; NB review at the time of PSUR reviews or substantial change reviews					
Periodic Safety Update Report (Article 86)		Updated at least annually; submitted to NB via EUDAMED for NB review					
Unannounced Audits (BSI policy as	At least once every 3 years						

### **Custom-made Class III implantable** devices



#### CUSTOM-MADE CLASS III IMPLANTABLE DEVICES


Custom-made Class III implantable devices	Initial Conformity	SURVEILLANCE				
	Assessment	Y1	Y2	Y3	Y4	Y5
QMS Audits	Yes	Yes	Yes	Recert	Yes	Yes
Microbiology Audits	Yes (if sterile)	N/A	Yes (if sterile)	N/A	Yes (if sterile)	N/A
Technical Documentation Assessment	N/A	N/A	N/A	N/A	N/A	N/A
Clinical Evaluation Consultation Procedure (Article 54)	N/A	N/A	N/A	N/A	N/A	N/A
Consultations (Rule 14, Rule 18, Rule 21)	N/A	N/A	N/A	N/A	N/A	N/A
Summary of Safety and Clinical Performance (Article 32)	N/A	N/A	N/A	N/A	N/A	N/A

Clinical Evaluation Report Updates	N/A	N/A	N/A	N/A	N/A	
Post Market Clinical Follow-Up Update Report (Article 61)	As per Manufacturer's PMS, PMCF plans; NB QMS audits to verify implementation of the plan					
Periodic Safety Update Report (Article 86)	Updated at least annually; unclear whether to be submitted to EUDAMED for NB review or not; NB to verify updates at the time of surveillance QMS audits					
Unannounced Audits (BSI policy as of Feb 2019)	At least once every 3 years					

# Custom-made devices


### (excluding custom-made Class III implantable devices)

Note: No Notified Body involvement



# **Class I** devices (excluding Class Is/Im/Ir devices)

Note: No Notified Body involvement



# Your resource for excellence

### Talk to BSI

- We have 4,600 colleagues globally
- Offices in 31 countries around the world
- Over 84,000 clients operating in 193 countries
- Together our clients account for 75% of the FTSE 100, 49% of the Fortune 500 and 77% of the Nikkei 225 listed companies
- Over 600 colleagues within medical devices.

#### Additional services

#### Medical device newsletter service

Keep updated on what's happening in the industry and changes in regulatory and quality requirements. You can take advantage of this free service by signing up on our website.

#### Informative webinars

Hear regular updates from our experts on key topics; listen live or listen back.

#### Comprehensive white papers

Our Technical Specialists collaborate with external experts to bring you the latest views and understanding on complex regulatory issues. Download your complimentary copies now.

#### Medical device guidance documents

Our online guidance documents provide assistance in understanding the regulatory requirements for medical devices.

#### Standards

BSI British Standards delivers leading-edge best practice solutions through the development and publication of more than 59,000 Standards and related products.

Your resource in worldwide compliance: call BSI today on +27(0)12 004 0279 or visit **bsigroup.com/en-ZA** – to start your journey.